1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial.

Authors :: Lepage, C.
Phelip, J.M.
Lièvre, A.
Le Malicot, K.
Tougeron, D.
Dahan, L.
Toumpanakis, C.
Di Fiore, F.
Bohas, C. Lombard
Borbath, I.
Coriat, R.
Caulet, M.
Guimbaud, R.
Petorin, C.
Legoux, J.L.
Scoazec, J-Y.
Michel, P.
Cadiot, G.
Smith, D.
Walter, T.
Source :: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS774-S774. 1p.
Publication Year :: 2020

Full Text Access

Tools